JPMorgan Chase & Co. Purchases 5,368 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

JPMorgan Chase & Co. raised its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 1.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 467,319 shares of the company’s stock after purchasing an additional 5,368 shares during the quarter. JPMorgan Chase & Co. owned 1.28% of iTeos Therapeutics worth $4,771,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of ITOS. nVerses Capital LLC grew its holdings in shares of iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after buying an additional 1,700 shares during the last quarter. Point72 DIFC Ltd bought a new position in iTeos Therapeutics in the 3rd quarter valued at about $31,000. China Universal Asset Management Co. Ltd. boosted its stake in iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares during the last quarter. Virtu Financial LLC bought a new stake in iTeos Therapeutics during the 3rd quarter worth approximately $102,000. Finally, Quest Partners LLC raised its stake in shares of iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after purchasing an additional 9,934 shares during the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Matthew Gall purchased 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

ITOS has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday. Wells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Finally, Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Friday, January 10th.

iTeos Therapeutics Trading Up 3.4 %

Shares of iTeos Therapeutics stock opened at $8.00 on Friday. The business’s fifty day simple moving average is $8.02 and its 200 day simple moving average is $11.58. iTeos Therapeutics, Inc. has a 12 month low of $7.09 and a 12 month high of $18.75. The firm has a market capitalization of $292.27 million, a P/E ratio of -2.54 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. Analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.